Peplomycin has been developed as novel analog of bleomycin, which has less pulmonary toxicity than bleomycin. Peplomycin has been the subject of extensive studies in Japan and Europe. It is indicated for the treatment of malignant lymphoma, head and neck cancer, lung cancer, prostate cancer and skin cancer. General side effects are: digestive symptoms such as stomatitis, anorexia, nausea/vomiting, general malaise, depilation, fever, chills etc.

Elliptinium is an antineoplastic agent, which was used in the treatment of metastatic breast cancer in France under the name Celiptium. The drug is known to intercalate into DNA and inhibit topoisomerase II. Several studies have demonstrated that this molecule can be oxidized, yielding a reactive electrophilic form, which is able to bind covalently to a nucleophilic biological molecule.

Aclarubicin (INN) or aclacinomycin A is an anthracycline drug is primarily indicated in conditions like Acute non-lymphoblastic leukemia, Breast cancer, Gastric cancer, Lymphoma, Ovarian coma, Small cell lung cancer, Thyroid cancer. Soil bacteria Streptomyces galilaeus can produce aclarubicin. Aclarubicin (HCl) is used in combination with different anticancerous drugs to obtain best therapeutic results and to reduce toxicity or side effects. Aclarubicin (HCl) is administered intravenously. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin.

Bisantrene was classed as an anthracycline chemotherapeutic agent. It inhibits replication, kills tumor cells in clonogenic assays, and intercalates with DNA, where it inhibits both DNA and RNA synthesis. Bisantrene preferentially binds to A-T rich regions of DNA, where it effects changes to supercoiling and initiates strand breaks in association with DNA-associated proteins. This results from the inhibition of the enzyme topoisomerase II, which relaxes DNA coiling during replication and transcription. Toxicity studies in dogs and monkeys revealed that leukopenia, anorexia, diarrhea injection site necrosis, enterocolitis, muscle degeneration, and pulmonary edema were observed with high doses. Bisantrene was found to have less associated cardiotoxicity than other anthracenes. The existing data for bisantrene clearly demonstrated activity in acute myeloid leukemia, and in other indications including lymphoma, refractory breast cancer, and ovarian cancer.

Pirarubicin is a new kind of anthracene nucleus broad-spectrum antitumor antibiotic. This compound was rapidly incorporated into tumor cells, inhibiting DNA polymerase alpha, DNA topoisomerase II and subsequently DNA synthesis. Inhibition of RNA synthesis was also noted. It is indicated as an antineoplastic agent for the treatment of the following diseases: head and neck cancer, breast cancer, gastric cancer, urothelial cancer, ovarian cancer, uterine cancer, acute leukemia, malignant lymphoma. Among the side effects, cardiac toxicity, alopecia and disturbance of the digestive organs were mild.

Bleomycin sulfate is an antineoplastic antibiotic isolated from Streptomyces verticillus. It is a mixture of glycopeptide antibiotics containing primarily Bleomycin A2 (~70%) and B2 (~30%). Bleomycin binds to DNA, inhibits DNA synthesis, and causes single strand scission of DNA in vivo and in vitro at specific base sequences.